Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

Bharat Nandakumar, Shaji K. Kumar, Angela Dispenzieri, Francis K. Buadi, David Dingli, Martha Q. Lacy, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Eli Muchtar, Rahma Warsame, Taxiarchis V. Kourelis, Stephen Russell, John A. Lust, Yi Lin, Ronald S. Go, Mustaqeem SiddiquiSteven Zeldenrust, Robert A. Kyle, Morie A. Gertz, S. Vincent Rajkumar, Wilson I. Gonsalves

Research output: Contribution to journalArticle

Abstract

Background: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical and cytogenetic features of NSMM in this study. Patients and Methods: This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester, MN, between 2008 and 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70% and more than one-half of all patients having Multiple Myeloma International Staging System Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort, accounting for more than 50% of the cohort. Finally, the overall survival of this cohort appears to be slightly worse than a matched-control group of newly diagnosed patients with MM with secretory disease. Conclusions: Future multi-institution studies confirming these above findings on this rare entity are warranted.

Original languageEnglish (US)
JournalClinical Lymphoma, Myeloma and Leukemia
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Multiple Myeloma
Cytogenetics
Therapeutics
Survival
Plasma Cells
Chromosome Aberrations
Bone Marrow Cells
Blood Proteins
Research Design
Urine
Control Groups

Keywords

  • Clinical outcomes
  • Myeloma survival
  • Non-secretory myeloma
  • Novel agents
  • t (11;14) cytogenetics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. / Nandakumar, Bharat; Kumar, Shaji K.; Dispenzieri, Angela; Buadi, Francis K.; Dingli, David; Lacy, Martha Q.; Hayman, Suzanne R.; Kapoor, Prashant; Leung, Nelson; Fonder, Amie; Hobbs, Miriam; Hwa, Yi Lisa; Muchtar, Eli; Warsame, Rahma; Kourelis, Taxiarchis V.; Russell, Stephen; Lust, John A.; Lin, Yi; Go, Ronald S.; Siddiqui, Mustaqeem; Zeldenrust, Steven; Kyle, Robert A.; Gertz, Morie A.; Rajkumar, S. Vincent; Gonsalves, Wilson I.

In: Clinical Lymphoma, Myeloma and Leukemia, 01.01.2019.

Research output: Contribution to journalArticle

Nandakumar, Bharat ; Kumar, Shaji K. ; Dispenzieri, Angela ; Buadi, Francis K. ; Dingli, David ; Lacy, Martha Q. ; Hayman, Suzanne R. ; Kapoor, Prashant ; Leung, Nelson ; Fonder, Amie ; Hobbs, Miriam ; Hwa, Yi Lisa ; Muchtar, Eli ; Warsame, Rahma ; Kourelis, Taxiarchis V. ; Russell, Stephen ; Lust, John A. ; Lin, Yi ; Go, Ronald S. ; Siddiqui, Mustaqeem ; Zeldenrust, Steven ; Kyle, Robert A. ; Gertz, Morie A. ; Rajkumar, S. Vincent ; Gonsalves, Wilson I. / Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. In: Clinical Lymphoma, Myeloma and Leukemia. 2019.
@article{fdc5a8f796ed42c7b27fed9469c666e5,
title = "Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy",
abstract = "Background: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical and cytogenetic features of NSMM in this study. Patients and Methods: This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester, MN, between 2008 and 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70{\%} and more than one-half of all patients having Multiple Myeloma International Staging System Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort, accounting for more than 50{\%} of the cohort. Finally, the overall survival of this cohort appears to be slightly worse than a matched-control group of newly diagnosed patients with MM with secretory disease. Conclusions: Future multi-institution studies confirming these above findings on this rare entity are warranted.",
keywords = "Clinical outcomes, Myeloma survival, Non-secretory myeloma, Novel agents, t (11;14) cytogenetics",
author = "Bharat Nandakumar and Kumar, {Shaji K.} and Angela Dispenzieri and Buadi, {Francis K.} and David Dingli and Lacy, {Martha Q.} and Hayman, {Suzanne R.} and Prashant Kapoor and Nelson Leung and Amie Fonder and Miriam Hobbs and Hwa, {Yi Lisa} and Eli Muchtar and Rahma Warsame and Kourelis, {Taxiarchis V.} and Stephen Russell and Lust, {John A.} and Yi Lin and Go, {Ronald S.} and Mustaqeem Siddiqui and Steven Zeldenrust and Kyle, {Robert A.} and Gertz, {Morie A.} and Rajkumar, {S. Vincent} and Gonsalves, {Wilson I.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clml.2019.09.624",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",

}

TY - JOUR

T1 - Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

AU - Nandakumar, Bharat

AU - Kumar, Shaji K.

AU - Dispenzieri, Angela

AU - Buadi, Francis K.

AU - Dingli, David

AU - Lacy, Martha Q.

AU - Hayman, Suzanne R.

AU - Kapoor, Prashant

AU - Leung, Nelson

AU - Fonder, Amie

AU - Hobbs, Miriam

AU - Hwa, Yi Lisa

AU - Muchtar, Eli

AU - Warsame, Rahma

AU - Kourelis, Taxiarchis V.

AU - Russell, Stephen

AU - Lust, John A.

AU - Lin, Yi

AU - Go, Ronald S.

AU - Siddiqui, Mustaqeem

AU - Zeldenrust, Steven

AU - Kyle, Robert A.

AU - Gertz, Morie A.

AU - Rajkumar, S. Vincent

AU - Gonsalves, Wilson I.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical and cytogenetic features of NSMM in this study. Patients and Methods: This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester, MN, between 2008 and 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70% and more than one-half of all patients having Multiple Myeloma International Staging System Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort, accounting for more than 50% of the cohort. Finally, the overall survival of this cohort appears to be slightly worse than a matched-control group of newly diagnosed patients with MM with secretory disease. Conclusions: Future multi-institution studies confirming these above findings on this rare entity are warranted.

AB - Background: Non-secretory multiple myeloma (NSMM) is a rare subtype of multiple myeloma (MM) characterized by the absence of monoclonal protein in the serum and/or urine. We look at the clinical and cytogenetic features of NSMM in this study. Patients and Methods: This study evaluates a cohort of 30 patients with newly diagnosed NSMM seen at the Mayo Clinic, Rochester, MN, between 2008 and 2018 and treated with novel agent induction therapies. Survival outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test. Results: These patients with NSMM appear to have a large disease burden at diagnosis with a median bone marrow plasma cell percentage of 70% and more than one-half of all patients having Multiple Myeloma International Staging System Stage III disease. There was a higher preponderance for t(11;14) primary cytogenetic abnormality in this NSMM cohort, accounting for more than 50% of the cohort. Finally, the overall survival of this cohort appears to be slightly worse than a matched-control group of newly diagnosed patients with MM with secretory disease. Conclusions: Future multi-institution studies confirming these above findings on this rare entity are warranted.

KW - Clinical outcomes

KW - Myeloma survival

KW - Non-secretory myeloma

KW - Novel agents

KW - t (11;14) cytogenetics

UR - http://www.scopus.com/inward/record.url?scp=85074419317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074419317&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.09.624

DO - 10.1016/j.clml.2019.09.624

M3 - Article

AN - SCOPUS:85074419317

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

ER -